Hoe verhoudt 34LA's PB Ratio zich tot zijn concurrenten?

34LA is duur op basis van de Price-To-Book -ratio ( 13.4 x) vergeleken met het gemiddelde van de peer ( 2.3 x).

Hoe verhoudt 34LA's PB Ratio zich tot andere bedrijven in de DE Biotechs industrie?

34LA is duur op basis van de Price-To-Book -ratio ( 13.4 x) vergeleken met het German Biotechs -industriegemiddelde ( 2 x).

Wat is 34LA's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { 34LA te berekenen voor waarderinganalyse.

Wat is de reële prijs van 34LA als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van 34LA te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is lager dan de huidige aandelenkoers.

Alpine Immune Sciences (DB:34LA) - Aandelenkoers, Nieuws & Analyse

34LA Overzicht aandelen

Operates as a clinical-stage biopharmaceutical company. Meer informatie

34LA fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 34.24% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

De winst zal naar verwachting de komende drie jaar met gemiddeld 9.9% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Alpine Immune Sciences, Inc. Concurrenten

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€857.2m

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Alpine Immune Sciences
Historische aandelenkoersen
Huidige aandelenkoers	US$59.00
52 Week Hoogtepunt	US$61.00
52 Week Laag	US$7.95
Bèta	0.97
11 maand verandering	-1.67%
3 maanden verandering	109.22%
1 Jaar Verandering	582.08%
33 jaar verandering	387.60%
5 jaar verandering	835.32%
Verandering sinds IPO	719.33%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	34LA	DE Biotechs	DE Markt
7D	-0.8%	0.8%	0.8%
1Y	582.1%	-18.3%	8.6%

Rendement versus industrie: 34LA overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -18.3 % opleverde.

Rendement versus markt: 34LA overtrof de German markt, die het afgelopen jaar een rendement opleverde van 8.6 %.

Prijsvolatiliteit

Is 34LA's price volatile compared to industry and market?
34LA volatility
34LA Average Weekly Movement	22.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 34LA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van 34LA is het afgelopen jaar gestegen van 17% naar 23%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	142	Mitch Gold	www.alpineimmunesciences.com

Alpine Immune Sciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Alpine Immune Sciences zich tot de beurswaarde?
34LA fundamentele statistieken
Marktkapitalisatie	€4.10b
Inkomsten(TTM)	-€33.88m
Inkomsten(TTM)	€51.99m

78.9x

P/S-verhouding

-121.0x

Koers/Winstverhouding

Is 34LA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
34LA resultatenrekening (TTM)
Inkomsten	US$56.52m
Kosten van inkomsten	US$83.78m
Brutowinst	-US$27.26m
Overige uitgaven	US$9.58m
Inkomsten	-US$36.84m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.54
Brutomarge	-48.23%
Nettowinstmarge	-65.17%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 34LA op de lange termijn?

Bekijk historische prestaties en vergelijking

34LA Overzicht aandelen

Beloningen

Risicoanalyse

Alpine Immune Sciences, Inc. Concurrenten

XTRA:BIO3

€1.3b

XTRA:FYB

€857.2m

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Full year 2023 earnings released: US$0.64 loss per share (vs US$1.73 loss in FY 2022)

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New major risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.60 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$1.73 loss per share (vs US$1.98 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2021)

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2021)

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought €84k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)

Alpine Immune Sciences Announces First Patient Dosed in Synergy, Alpn-101 Phase 2 Lupus Clinical Trial and $45 Million in Development Milestones Achieved Under Abbvie Collaboration

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at 2021 American Society of Clinical Oncology Virtual Annual Meeting

Alpine Immune Sciences, Inc. Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.30 loss in 1Q 2020)

Full year 2020 earnings released: US$1.34 loss per share (vs US$2.28 loss in FY 2019)

Alpine Immune Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Alpine Immune Sciences, Inc. Announces Executive Changes

New 90-day high: €11.80

Alpine Immune Sciences Appoints Natasha A. Hernday to its Board of Directors

New 90-day high: €7.70

Independent Director recently bought €68k worth of stock

Third quarter 2020 earnings released: US$0.28 loss per share

Revenue misses expectations